Chronic Kidney Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata The

DelveInsight's, "Crohn's disease - Pipeline Insight, 2025" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Crohn's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chronic Kidney Disease Pipeline constitutes 80+ key companies continuously working towards developing 85+ Chronic Kidney Disease treatment therapies, analyzes DelveInsight.

Chronic Kidney Disease Overview:

Chronic Kidney Disease (CKD) is a long-term condition characterized by the gradual loss of kidney function over time. The kidneys are essential for filtering waste, excess fluids, and electrolytes from the bloodstream, which are excreted in urine. As CKD worsens, it can lead to kidney failure, requiring dialysis or a kidney transplant to sustain life. The condition is categorized into five stages, with Stage 1 being mild and Stage 5 indicating end-stage renal disease (ESRD).

CKD often develops silently, with few or no symptoms in the early stages. As it progresses, individuals may experience fatigue, swelling in the legs and ankles, appetite loss, nausea, vomiting, shortness of breath, itching, and changes in urination. In advanced stages, complications such as high blood pressure, anemia, bone weakness, and nerve damage may occur. Severe cases can lead to uremia, a dangerous buildup of toxins in the blood, which may cause confusion, difficulty concentrating, or seizures.

The most common causes of CKD are diabetes and high blood pressure. Other contributing factors include glomerulonephritis, polycystic kidney disease, chronic urinary tract obstructions, repeated kidney infections, and autoimmune disorders like lupus. The disease progresses due to a combination of factors such as increased pressure in the kidney's filtering units (glomerular hyperfiltration), ongoing inflammation, tissue scarring (fibrosis), and cell damage, all of which contribute to declining kidney function over time.

Request for a detailed insights report on Chronic Kidney Disease pipeline insights [https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Chronic Kidney Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Kidney Disease Therapeutics Market.

Key Takeaways from the Chronic Kidney Disease Pipeline Report

*
DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Chronic Kidney Disease treatment.

*
In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the U.S. FDA had accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). The FDA has set a target action date of June 28, 2025, under the Prescription Drug User Fee Act (PDUFA). If approved, OLC could represent a significant breakthrough in treating hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis.

*
In March 2023, Boehringer Ingelheim shared promising Phase II results for BI-690517, a novel selective aldosterone synthase inhibitor (ASI). The 14-week study showed a substantial reduction in albuminuria, a key indicator of kidney damage, by up to 39.5% when BI-690517 was combined with empagliflozin, an SGLT2 inhibitor, compared to a placebo. This was the first clinical trial to evaluate this new treatment class alongside standard care in CKD patients, with the results presented at the American Society of Nephrology's Kidney Week 2023.

*
Key Chronic Kidney Disease companies such as Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata Therapeutics, Unicycive Therapeutics, Novo Nordisk, Bayer, AstraZeneca, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Boehringer Ingelheim, SCOHIA PHARMA, Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Disc Medicine, Shandong Suncadia Medicine, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Healx, Benevolent, and others are evaluating new drugs for Chronic Kidney Disease to improve the treatment landscape.

*
Promising Chronic Kidney Disease pipeline therapies in various stages of development include Ziltivekimab, Rilparencel, US-APR2020, XRx-008, CLBS201, UNI-494, and others.

Chronic Kidney Disease Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Chronic Kidney Disease Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Kidney Disease market.

Download our free sample page report on Chronic Kidney Disease pipeline insights [https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Kidney Disease Emerging Drugs

*
Ziltivekimab: Novo Nordisk

*
Rilparencel: Prokidney

*
US-APR2020: Kibow Pharma

*
XRx-008: XORTX Therapeutics

*
CLBS201: Lisata Therapeutics

*
UNI-494: Unicycive Therapeutics

Chronic Kidney Disease Companies

More than 80 major companies are actively developing treatments for Chronic Kidney Disease (CKD). Among these, Novo Nordisk has advanced its drug candidates to the furthest stage of development-Phase III clinical trials.

DelveInsight's report covers around 85+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Chronic Kidney Disease Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Kidney Disease Therapies and Key Companies: Chronic Kidney Disease Clinical Trials and advancements [https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Kidney Disease Pipeline Therapeutic Assessment

- Chronic Kidney Disease Assessment by Product Type

- Chronic Kidney Disease By Stage

- Chronic Kidney Disease Assessment by Route of Administration

- Chronic Kidney Disease Assessment by Molecule Type

Download Chronic Kidney Disease Sample report to know in detail about the Chronic Kidney Disease treatment market @ Chronic Kidney Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Chronic Kidney Disease Current Treatment Patterns

4. Chronic Kidney Disease - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Chronic Kidney Disease Late-Stage Products (Phase-III)

7. Chronic Kidney Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Kidney Disease Discontinued Products

13. Chronic Kidney Disease Product Profiles

14. Chronic Kidney Disease Key Companies

15. Chronic Kidney Disease Key Products

16. Dormant and Discontinued Products

17. Chronic Kidney Disease Unmet Needs

18. Chronic Kidney Disease Future Perspectives

19. Chronic Kidney Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chronic Kidney DiseaseO Pipeline Reports Offerings [https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-kidney-disease-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-novo-nordisk-prokidney-kibow-pharma-xortx-therapeutics-lisata-the]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.